4D MOLECULAR THERAPEUTICS IN (FDMT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:FDMT • US35104E1001

9.49 USD
+0.34 (+3.72%)
At close: Feb 3, 2026
9.49 USD
0 (0%)
After Hours: 2/3/2026, 8:14:36 PM
Fundamental Rating

3

FDMT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for FDMT as it has an excellent financial health rating, but there are worries on the profitability. FDMT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year FDMT has reported negative net income.
  • FDMT had a negative operating cash flow in the past year.
  • FDMT had negative earnings in each of the past 5 years.
  • FDMT had a negative operating cash flow in each of the past 5 years.
FDMT Yearly Net Income VS EBIT VS OCF VS FCFFDMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • FDMT has a Return On Assets (-49.34%) which is in line with its industry peers.
  • FDMT's Return On Equity of -56.69% is fine compared to the rest of the industry. FDMT outperforms 63.74% of its industry peers.
Industry RankSector Rank
ROA -49.34%
ROE -56.69%
ROIC N/A
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
FDMT Yearly ROA, ROE, ROICFDMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for FDMT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FDMT Yearly Profit, Operating, Gross MarginsFDMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K -500K

More info and screens

7

2. Health

2.1 Basic Checks

  • FDMT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, FDMT has more shares outstanding
  • FDMT has more shares outstanding than it did 5 years ago.
  • FDMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
FDMT Yearly Shares OutstandingFDMT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
FDMT Yearly Total Debt VS Total AssetsFDMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 2.26 indicates that FDMT is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 2.26, FDMT is in the better half of the industry, outperforming 66.79% of the companies in the same industry.
  • FDMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.26
ROIC/WACCN/A
WACC8.93%
FDMT Yearly LT Debt VS Equity VS FCFFDMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 8.42 indicates that FDMT has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 8.42, FDMT is doing good in the industry, outperforming 75.95% of the companies in the same industry.
  • FDMT has a Quick Ratio of 8.42. This indicates that FDMT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 8.42, FDMT is in the better half of the industry, outperforming 75.95% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.42
Quick Ratio 8.42
FDMT Yearly Current Assets VS Current LiabilitesFDMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

  • FDMT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.51%.
  • Looking at the last year, FDMT shows a very negative growth in Revenue. The Revenue has decreased by -99.42% in the last year.
  • Measured over the past years, FDMT shows a very negative growth in Revenue. The Revenue has been decreasing by -64.95% on average per year.
EPS 1Y (TTM)-32.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.85%
Revenue 1Y (TTM)-99.42%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%2900%

3.2 Future

  • The Earnings Per Share is expected to decrease by -6.84% on average over the next years.
  • The Revenue is expected to grow by 132.60% on average over the next years. This is a very strong growth
EPS Next Y-25.86%
EPS Next 2Y-9.12%
EPS Next 3Y-5.67%
EPS Next 5Y-6.84%
Revenue Next Year405.19%
Revenue Next 2Y263.72%
Revenue Next 3Y140.6%
Revenue Next 5Y132.6%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FDMT Yearly Revenue VS EstimatesFDMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
FDMT Yearly EPS VS EstimatesFDMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • FDMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FDMT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FDMT Price Earnings VS Forward Price EarningsFDMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FDMT Per share dataFDMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • A cheap valuation may be justified as FDMT's earnings are expected to decrease with -5.67% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.12%
EPS Next 3Y-5.67%

More info and screens

0

5. Dividend

5.1 Amount

  • FDMT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

4D MOLECULAR THERAPEUTICS IN

NASDAQ:FDMT (2/3/2026, 8:14:36 PM)

After market: 9.49 0 (0%)

9.49

+0.34 (+3.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)02-27
Inst Owners72.01%
Inst Owner Change-0.96%
Ins Owners3.16%
Ins Owner Change0.17%
Market Cap542.26M
Revenue(TTM)120.00K
Net Income(TTM)-209.18M
Analysts82.35
Price Target33.77 (255.85%)
Short Float %17.15%
Short Ratio10.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.45%
Min EPS beat(2)-9.71%
Max EPS beat(2)-1.18%
EPS beat(4)1
Avg EPS beat(4)-4.14%
Min EPS beat(4)-9.71%
Max EPS beat(4)2.21%
EPS beat(8)4
Avg EPS beat(8)-0.12%
EPS beat(12)7
Avg EPS beat(12)5.39%
EPS beat(16)10
Avg EPS beat(16)5.21%
Revenue beat(2)0
Avg Revenue beat(2)-82.71%
Min Revenue beat(2)-96.07%
Max Revenue beat(2)-69.35%
Revenue beat(4)0
Avg Revenue beat(4)-90.44%
Min Revenue beat(4)-99.94%
Max Revenue beat(4)-69.35%
Revenue beat(8)1
Avg Revenue beat(8)28.44%
Revenue beat(12)2
Avg Revenue beat(12)14.25%
Revenue beat(16)3
Avg Revenue beat(16)0.78%
PT rev (1m)0%
PT rev (3m)8.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)14.46%
EPS NY rev (1m)0%
EPS NY rev (3m)0.46%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)183.41%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)118.59%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4518.82
P/FCF N/A
P/OCF N/A
P/B 1.47
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)-3.75
EYN/A
EPS(NY)-3.55
Fwd EYN/A
FCF(TTM)-3.24
FCFYN/A
OCF(TTM)-3.21
OCFYN/A
SpS0
BVpS6.46
TBVpS6.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.34%
ROE -56.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.14%
ROA(5y)-27.85%
ROE(3y)-36.91%
ROE(5y)-31.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.44%
Cap/Sales 1295.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.42
Quick Ratio 8.42
Altman-Z 2.26
F-Score2
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)209.37%
Cap/Depr(5y)259.38%
Cap/Sales(3y)3538.16%
Cap/Sales(5y)2134.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-27.85%
EPS Next Y-25.86%
EPS Next 2Y-9.12%
EPS Next 3Y-5.67%
EPS Next 5Y-6.84%
Revenue 1Y (TTM)-99.42%
Revenue growth 3Y-87.29%
Revenue growth 5Y-64.95%
Sales Q2Q%2900%
Revenue Next Year405.19%
Revenue Next 2Y263.72%
Revenue Next 3Y140.6%
Revenue Next 5Y132.6%
EBIT growth 1Y5.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.13%
EBIT Next 3Y-14.19%
EBIT Next 5YN/A
FCF growth 1Y-141.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-150.13%
OCF growth 3YN/A
OCF growth 5YN/A

4D MOLECULAR THERAPEUTICS IN / FDMT FAQ

What is the fundamental rating for FDMT stock?

ChartMill assigns a fundamental rating of 3 / 10 to FDMT.


What is the valuation status of 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?

ChartMill assigns a valuation rating of 0 / 10 to 4D MOLECULAR THERAPEUTICS IN (FDMT). This can be considered as Overvalued.


How profitable is 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?

4D MOLECULAR THERAPEUTICS IN (FDMT) has a profitability rating of 1 / 10.


What is the financial health of 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?

The financial health rating of 4D MOLECULAR THERAPEUTICS IN (FDMT) is 7 / 10.